Jain Global’s BridgeBio Pharma BBIO Stock Holding History

Jain Global’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-66,752	Closed	-$3.47M	–	1234
2025 Q3	$3.47M	Buy	+66,752	New	+$3.26M	0.02%	431
2025 Q2	–	Sell	-118,007	Closed	-$4.08M	–	1197
2025 Q1	$4.08M	Buy	118,007 +65,553	+125%	+$2.21M	0.05%	261
2024 Q4	$1.44M	Buy	+52,454	New	+$1.36M	0.04%	273

Other funds holding BBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jain Global's BBIO Position: Q4 2025 in Review

Jain Global sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 66,752 shares — an estimated $3.47M sold.

Jain Global first reported a position in BBIO in Q4 2024 and held it in 3 quarters. The position peaked at $4.08M in Q1 2025. 433 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

Jain Global reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
Jain Global sold 66,752 BridgeBio Pharma shares in Q4 2025, an estimated $3.47M.
Jain Global first reported a position in BridgeBio Pharma in Q4 2024 and held it in 3 quarters.
Jain Global's BridgeBio Pharma position peaked at $4.08M in Q1 2025.
433 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Jain Global's 13F filing for Q4 2025, filed 17 Feb 2026.